Showing results (691-700 of 942) with videos related to
Sort By:
Pageof 95
European Heart Journal|July 3, 2004
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studiesDavid A Morrow, Elliott M Antman, Sabina A Murphy, et al.Journal of the American Heart Association|March 21, 2015
Efficacy and safety of vorapaxar as approved for clinical use in the United StatesGiulia Magnani, Marc P Bonaca, Eugene Braunwald, et al.Diabetes, Obesity & Metabolism|July 26, 2024
Risk of new-onset diabetes and efficacy of pharmacological weight loss therapyFilipe A Moura, Andrea Bellavia, David D Berg, et al.American Journal of Epidemiology|October 9, 2025
Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trialsRobert Thiesmeier, Paul M Haller, Siddharth M Patel, et al.Congestive Heart Failure (Greenwich, Conn.)|December 18, 2004
BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseasesMarc A Silver, Alan Maisel, Clyde W Yancy, et al.Journal of the American Heart Association|April 26, 2022
Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease RegistryAnkeet S Bhatt, Anubodh S Varshney, Erica L Goodrich, et al.Circulation|November 18, 2005
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 TrialMarc S Sabatine, David A Morrow, Gilles Montalescot, et al.Journal of Cardiac Failure|February 16, 2023
Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure EventRobert J Mentz, Jonathan H Ward, Adrian F Hernandez, et al.Circulation|March 21, 2007
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery diseaseMarc S Sabatine, David A Morrow, Kathleen A Jablonski, et al.JAMA Cardiology|September 30, 2016
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical TrialBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.Pageof 95